Glycinamide Ribonucleotide Formyltransferase Inhibitors
6 drugsAbout Glycinamide Ribonucleotide Formyltransferase
Glycinamide Ribonucleotide Formyltransferase is an enzyme essential for purine biosynthesis, catalyzing a key step in inosine monophosphate (IMP) formation. By enabling the production of adenosine and guanosine nucleotides, it supports DNA and RNA synthesis. Inhibiting this enzyme disrupts nucleotide synthesis, hindering cell growth and proliferation.
As a critical enzyme for nucleotide production, Glycinamide Ribonucleotide Formyltransferase is a therapeutic target in rapidly dividing cells like cancerous tumors. Currently, there is no genetic evidence directly linking this target to specific diseases, but its role in nucleotide metabolism makes it compelling.
Glycinamide Ribonucleotide Formyltransferase is targeted by six FDA-approved small molecule drugs, including PEMETREXED DISODIUM (ALIMTA), AXTLE, PEMETREXED, and PEMFEXY, all for oncology indications. These drugs are marketed by six companies including QILU PHARM HAINAN, AVYXA HOLDINGS, SHILPA, EAGLE PHARMS, and Eli Lilly.
Strategic Insights
ℹ️ How we calculate- phase2 represents biological uncertainty with 43% completion.
Top Glycinamide Ribonucleotide Formyltransferase Drugs
Six companies have approved drugs targeting Glycinamide Ribonucleotide Formyltransferase, indicating a moderately competitive landscape.
Consider partnerships or acquisitions to consolidate market share and reduce competitive pressure.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| ALIMTA | Eli Lilly | 2004 | 2 |
| PEMFEXY | EAGLE PHARMS | 2020 | 2 |
| PEMETREXED FOR INJECTION | Dr. Reddy's | - | 2 |
Glycinamide Ribonucleotide Formyltransferase Drug Modality Landscape
Modalities
Routes of Administration
Glycinamide Ribonucleotide Formyltransferase is druggable by small molecules, though no oral formulations are currently approved.
Explore alternative modalities like PROTACs or biologics to differentiate from existing therapies.
Glycinamide Ribonucleotide Formyltransferase Clinical Trials 718 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 197 | 82 | 40 | 75 | 67% |
| Phase 2 | 325 | 94 | 78 | 150 | 55% |
| Phase 3 | 183 | 57 | 26 | 98 | 69% |
| Phase 4 | 13 | 6 | 3 | 4 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved Glycinamide Ribonucleotide Formyltransferase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Glycinamide Ribonucleotide Formyltransferase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Glycinamide Ribonucleotide Formyltransferase Drug Approval Timeline (2004 - 2024)
The first drug was approved in 2004 (ALIMTA), with the most recent approval in 2024 (AXTLE), spanning 21 years.
The continued approvals suggest sustained interest, but saturation may increase regulatory hurdles for new entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 6 companies competing
- • Market share by company
Full Drug Portfolio
- • All 6 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 6-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 543 clinical trials targeting Glycinamide Ribonucleotide Formyltransferase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities